Boccalini Sara, Bechini Angela, Moscadelli Andrea, Paoli Sonia, Schirripa Annamaria, Bonanni Paolo
Department of Health Sciences, University of Florence, Florence, Italy.
Specialization Medical School of Hygiene. Department of Health Sciences, University of Florence, Florence, Italy.
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):911-922. doi: 10.1080/14737167.2021.1925110. Epub 2021 May 13.
: Influenza can be a significant public health problem. Nevertheless, it is preventable through vaccination. Concerning the pediatric population, the recommendation of influenza vaccination is under-represented in many European countries. The aim of this systematic review is to evaluate the cost-effectiveness of universal childhood vaccination against influenza in Europe.: We conducted a systematic review of original article assessing the cost-effectiveness of influenza vaccination by searching PubMed, Embase and Scopus databases for studies in English, starting from January 1, 2010 up to October 21, 2020.: Our literature review showed that all studies identified highlight that pediatric vaccinations using a live vaccine, especially in the quadrivalent formulation, are cost-effective compared to current vaccinations (elderly and at-risk groups) with TIV or no vaccination. A significant contribution to this positive economic profile is due to the indirect protection. Already many clinical data report the relevant direct and indirect impact of vaccination against influenza for younger subjects. The recent studies collected in this review showed also that the pediatric vaccination is also cost-effective. Therefore, decision-makers should now consider this new favorable evidence.
流感可能是一个重大的公共卫生问题。然而，通过接种疫苗可以预防。关于儿童群体，在许多欧洲国家，流感疫苗接种的建议未得到充分体现。本系统评价的目的是评估欧洲普遍儿童流感疫苗接种的成本效益。
我们通过检索PubMed、Embase和Scopus数据库，对2010年1月1日至2020年10月21日期间发表的英文研究进行了系统评价，以评估流感疫苗接种的成本效益。
我们的文献综述表明，所有纳入的研究均强调，与目前针对老年人和高危人群接种三价灭活疫苗或不接种疫苗相比，使用活疫苗（尤其是四价配方）进行儿童疫苗接种具有成本效益。这种积极的经济状况很大程度上归因于间接保护。已经有许多临床数据报告了流感疫苗接种对较年轻人群的相关直接和间接影响。本次综述中收集的最新研究还表明，儿童疫苗接种也具有成本效益。因此，决策者现在应考虑这一新的有利证据。
